Infliximab Pharmacokinetics, Dosing, and Response in Hospitalized Patients with COVID-19 Pneumonia: A Secondary Analysis of a Multinational Randomized Clinical Trial (ACTIV-1 IM)
Abstract
Infliximab may play an important role in reducing mortality in severe COVID‐19, though optimal dosing is unknown. This secondary analysis of the ACTIV‐1 IM trial characterized infliximab pharmacokinetics and outcomes in patients hospitalized with severe COVID‐19. ACTIV‐1 IM included patients admitted with COVID‐19 pneumonia who received infliximab in addition to routine care. Infliximab was administered as a single 5‐mg/kg intravenous dose. The primary exposure variable was predicted infliximab concentrations over 28 days (AUC0‐28). Logistic regression modeling was used to relate AUC0‐28 to the primary outcome of 28‐day mortality, adjusted for age. The relationship between AUC0‐28 and the secondary outcome of time to recovery was evaluated using a Fine–Gray model, adjusted for age, with death as a competing risk. AUC0‐28 was higher in patients who did not die versus those who died, with a median (range) of 20,681 mg h/L (8379‐60,322) versus 17,392 (9543‐43,145), P 17,400 mg h/L, albeit at a lower rate (1.18‐fold higher [95% CI 1.07‐1.32]), P < .002 for both. Overall, 113/390 (29.0%) patients did not achieve an optimal predicted infliximab AUC0‐28 of at least 17,400 mg h/L, particularly those <100 kg and those with the highest baseline disease severity.
How strong is the evidence?
Evidence Hub reads this as a secondary / pooled analysis, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Levofloxacin-Induced Tendon Rupture: A Case Report and Review of the Literature
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- Neuroprotective Effects of Epicatechin against Oxidative Stress-Induced Cognitive Impairment: A Systematic Review and Meta-Analysis
- Quality evaluation and in vitro interaction studies between levofloxacin 250mg and diclofenac sodium 50mg tablets
- Molecular Epidemiology of mcr-1 -Positive Polymyxin B-Resistant Escherichia coli Producing Extended-Spectrum β-Lactamase (ESBL) in a Tertiary Hospital in Shandong, China
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.